Cancer Research Cancer Epigenetics  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 6007, August 1, 2009. Published Online First July 28, 2009;
doi: 10.1158/0008-5472.CAN-09-0756
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0008-5472.CAN-09-0756v1
69/15/6007    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Theunissen, J.-W.
Right arrow Articles by de Sauvage, F. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theunissen, J.-W.
Right arrow Articles by de Sauvage, F. J.

Reviews

Paracrine Hedgehog Signaling in Cancer

Jan-Willem Theunissen and Frederic J. de Sauvage

Department of Molecular Biology, Genentech Inc., South San Francisco, California

Requests for reprints: Frederic J. de Sauvage, Department of Molecular Biology, Genentech Inc., Mailstop 37, 460 Point San Bruno Blvd., South San Francisco, CA 94080. Phone: 650-225-5841; Fax: 650-225-6497; E-mail: sauvage{at}gene.com.

Ligand-dependent and ligand-independent activation of the Hedgehog (Hh) signaling pathway is involved in tumorigenesis. The importance of mutations in Hh pathway components leading to constitutive signaling has been well established in basal cell carcinoma and medulloblastoma. However, the role of ligand-driven Hh pathway activation in cancer remains to be established. Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth. These data have important implications for the use of Hh pathway inhibitors currently in development and for selection of tumors likely to respond to such inhibitors. [Cancer Res 2009;69(15):6007–10]




This article has been cited by other articles:


Home page
CRO ContentHome page
G. C. Prendergast
Unifying Insights into Cancer Cell Signaling: Hedgehog, Cell Polarity, Complement, and CTLA-4 Polymorphisms
Cancer Reviews Online Content, January 1, 2009; 2009(9): 17 - 18.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.